Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Oral dutasteride and topical pimecrolimus can safely and effectively treat Frontal Fibrosing Alopecia, leading to significant hair regrowth.

This study suggests a potential role for systematic scalp examinations in first-degree relatives of patients with pattern cicatricial alopecia.

This study found that transient inhibition of eIF4E in a transgenic mouse model protected against cyclophosphamide-induced hair loss by inducing cell cycle arrest and reducing cellular apoptosis.

Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.

In this study, researchers discovered that fat grafting helps reduce dermal fibrosis in radiation-injured mouse skin by decreasing specific fibroblast subpopulations associated with Fra/c-Jun signaling.

This study found that invasomes enhanced the iontophoretic transdermal delivery of finasteride in rabbits, increasing AUC and T1/2 compared to oral suspension.

This study identified orally available itaconate derivatives that improve cellular permeability and bioavailability, with specific POC-based prodrugs showing significant inhibition of inflammatory cytokines in human epidermal keratinocytes and favorable oral pharmacokinetics, highlighting their potential for treating systemic and skin disorders.

This study found that eyelash loss, facial papules, and body hair involvement were linked to severe frontal fibrosing alopecia, and antiandrogens were the most effective treatment.

This study introduces ficlatuzumab, an anti-HGF monoclonal antibody, in combination with gefitinib in a phase 2 trial to address EGFR TKI resistance in Asian NSCLC patients.

This study observed that many couples in North America undergo IUI or IVF for male infertility without specialized male factor evaluations, potentially overlooking reversible causes.

This study found that Follicular Maps, derived from trichoscopic images, remained consistent over time and unaffected by hair cycling or noncicatricial alopecia, offering a precise tool for diagnosing and monitoring hair and scalp conditions.

No results are provided in this article as it lacks an available abstract, making it unclear what effects apremilast and tofacitinib have in a humanized mouse model of alopecia areata.

This study observed that patients with androgenetic alopecia had significantly higher serum FABP4 levels compared to healthy controls, suggesting FABP4 may be involved in the condition's pathogenesis.

This study suggests that oral tofacitinib may be an effective treatment for beard regrowth in men with alopecia areata of the beard, with a strong correlation observed between beard and scalp hair regrowth.

Targeting immune pathways like JAK/STAT may help treat frontal fibrosing alopecia.

In this pediatric retrospective study, tofacitinib (a Janus kinase inhibitor) improved the severity of alopecia and quality of life more effectively than traditional treatment methods, with significant reductions in alopecia severity score and dermatology life quality index over 16 weeks.

In this study, IPL treatment for six months significantly reduced hair growth in females with faun tail nevus linked to spinal abnormalities.

This review describes techniques to manage intraoperative floppy iris syndrome linked to alpha-1 blocker use in cataract surgery, highlighting the need for patient disclosure of medication use but reports no new clinical results.

Recognizing IPPP is crucial to prevent misdiagnosis and unnecessary treatments.

In this study, pediatric patients with alopecia areata treated with systemic tofacitinib showed significant improvement at 12 months, but the small sample size and retrospective design limit conclusions about its effectiveness.

This study found that novel RNA aptamers specifically inhibited FGF5-induced cell proliferation, suggesting their potential as candidates for treating FGF5-related diseases or hair disorders.

This study suggests that young females may experience a rare coexistence of Frontal Fibrosing Alopecia and ophiasis pattern Alopecia Areata, possibly sharing a common underlying pathophysiology.

In this study, the authors emphasize that IFK, though rare in young patients, should be considered when diagnosing scalp lesions in all age groups, highlighting the importance of recognizing its dermoscopic and histopathologic features to avoid misdiagnosis and ensure proper management.

This review discusses how JAK inhibitors, like tofacitinib and baricitinib, show promise in improving conditions like lichen planopilaris and frontal fibrosing alopecia by reducing severity scores and enhancing hair regrowth, though further research on safety and personalized approaches is needed.

In this study, oral tofacitinib significantly reduced alopecia severity in pediatric patients with moderate-to-severe alopecia areata over 24 weeks, with 42.2% achieving complete or near-complete hair regrowth, although further research is needed on long-term safety and relapse rates.

This study observed that tofacitinib therapy over about 16 weeks had a positive effect in children with alopecia areata, reducing the SALT index significantly in some patients.

In this case study, a 5-year-old girl with alopecia areata and atopic dermatitis that were unresponsive to previous treatments achieved substantial improvement with long-term tofacitinib, highlighting its potential safety and efficacy in managing both conditions concurrently.

This study found that key amino acids lost from hair due to weathering can be successfully reintroduced through cosmetic treatments, improving hair strength and aesthetics.

In this study, researchers observed that inoculation with Funneliformis mosseae significantly enhanced growth, biomass, and root architecture in trifoliate orange plants, with variations in auxin levels and gene expression, suggesting PtPIN6 as a key gene involved in root hair development regulation.